Immunovaccine to Present Preclinical DepoVax(TM) Therapeutic Cancer Vaccine Research at the International Society for Biological Therapy of Cancer (iSBTc) Conference
HALIFAX, NOVA SCOTIA -- (MARKET WIRE) -- 09/28/10 -- Immunovaccine Inc. (TSX VENTURE: IMV) announced today the Company will present a research poster entitled "Tumor Elimination by DepoVax Cancer Vaccine Platform is Accompanied by Reduced Regulatory or Suppressor Cell Infiltration" at the International Society for Biological Therapy of Cancer (iSBTc) conference. The conference is being held in Washington, D.C. from October 1-4, 2010.
The highlight of the study is the tumor elimination caused by the DepoVax-based therapeutic cancer vaccine in animal models. This result can be viewed in real-time MRI video imaging at www.imvaccine.com/canvac.php.
The vaccine-induced protection of the animal model is also accompanied by a more than two-fold reduction in the levels of immune suppressing cells such as Treg, MDSC, Tr1 and activated Treg cells found in the tumor and various lymphoid organs. In these animal studies, the DepoVax-based vaccine is compared directly with a commonly used emulsion-based control vaccine. By maintaining normal low levels of regulatory cells following the injection of the DepoVax-based vaccine, a sustained and desired immune response is generated.
"The combined ability to induce an effective immune response without inducing an immune-suppressor response highlights the potential for DepoVax-based therapeutic cancer vaccines in the clinic," said Dr. Marc Mansour, Immunovaccine's vice president of research and development.
Immunovaccine is currently testing the safety and tolerability of DepoVax in a Phase 1 clinical trial with DPX-0907, a therapeutic cancer vaccine, targeting patients with breast, ovarian and prostate cancer.
The poster presentation will be available online on October 1, 2010 at www.deliveringbreakthroughs.com.
The iSBTc conference hosts over 500 of the world's top cancer researchers and doctors who will present cutting-edge findings in cancer immunotherapy research and clinical translations. Journalists wishing to attend the 2010 iSBTc conference must register at www.isbtc.org/UserFiles/file/AM10%20Press%20Reg.pdf.
Immunovaccine Inc. (TSX VENTURE: IMV) is a clinical stage vaccine development company focused on the commercialization of its patented DepoVax vaccine delivery technology and product candidates. The company continues to strengthen its vaccine pipeline through licensing and strategic partnerships to develop therapeutic cancer and infectious disease vaccines.
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts: Tiberend Strategic Advisors, Inc. Andrew Mielach (212) 827-0020 [email protected] Immunovaccine Inc. Jennifer Ayotte Director Communications (902) 209-4704 [email protected] www.imvaccine.com
Released September 28, 2010